Contents available at ITME Online Repository

INNOVATIVE TRENDS IN MULTIDISCIPLINARY ENGINEERING

International Peer-Reviewed Journal of the School of Engineering & Technology

K.R. Mangalam University, Gurugram

Journal Homepage: **https://itme.krmangalam.edu.in/**



Artificial Intelligence in Depression Care: From Early Detection to Personalized Treatment and Future Directions

Divyanshu Singh[a,*], **Ashutosh Singh**[a], **Awaneet Kaur**[a], **Debashis Pramanick**[b]

[a] *School of Medical and Allied Science, Galgotias University, Greater Noida 203201, India*
[b] *School of Medical and Allied Science, KR Mangalam University, India*

DOI: 10.68343/ITME.2026.0102.8

ARTICLE INFO

Article history:
Received 22 March 2026
Revised 9 May 2026
Accepted 15 May 2026
Available online DD Month 2026

Keywords:
Artificial Intelligence
Depression
Machine Learning
Natural Language Processing
Digital Psychiatry
Early Detection
Personalized Treatment

ABSTRACT

Depression is a leading global mental health disorder affecting more than 280 million people worldwide, with conventional diagnostic and therapeutic approaches limited by subjectivity, delayed detection, and variability in treatment response. Artificial intelligence (AI) has emerged as a transformative approach enabling more objective, scalable, and data-driven depression care. This review synthesizes advances in AI for early detection, clinical diagnosis, and personalized treatment, examining machine learning, deep learning, and natural language processing applied to multimodal data including speech, facial expressions, social media behavior, wearable sensor data, and neuroimaging. It highlights AI-enabled interventions such as digital phenotyping, predictive modeling, and chatbot-assisted cognitive behavioral therapy. Despite promising outcomes, challenges persist including data privacy, algorithmic bias, limited generalizability, and the need for robust clinical validation. The paper concludes with future research directions and the integration of AI into digital psychiatry.

1. Introduction

Major depressive disorder (MDD) affects millions worldwide and is a leading contributor to the global disease burden, ranking among the top causes of years lived with disability and increasing in prevalence due to socio-environmental factors such as pandemics, wars, and displacement [1]. Its wide range of symptoms affecting mood, cognition, and daily functioning makes diagnosis and management challenging [2]. Despite high prevalence, depression frequently goes unrecognized or untreated where access is limited; stigma, professional shortages, and restricted access drive this treatment gap [3], further complicated by frequent comorbidity with other psychiatric and chronic conditions [4]. Conventional methods (clinical interviews and self-report questionnaires) rely on subjective assessment, where errors may delay diagnosis by years [5], while pharmacotherapy and psychotherapy often follow trial-and-error approaches that prolong time to effective treatment [6]. These methods struggle to capture the dynamic, multifaceted nature of depression arising from biological, psychological, and environmental interactions, contributing to delayed detection and difficult monitoring [7]. Socioeconomic barriers widen the gap further, particularly in low- and middle-income countries [8].

AI is rapidly transforming mental health care, enabling individualized identification, classification, and intervention. Using machine learning (ML), deep learning (DL), and natural language processing (NLP), AI

* Corresponding author. E-mail: **rmsdivyanshusingh@gmail.com**

© 2026 The Authors. Published by K.R. Mangalam University, Gurugram.
Selection and double-blind peer-review under the responsibility of School of Engineering & Technology.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0).

can analyze large multimodal datasets such as clinical records, brain scans, speech, and digital behavior [9]. Recent research indicates AI algorithms can reliably classify depressive symptoms and predict disease progression, often outperforming traditional methods; for example, DL can analyze biomarkers and behavioral characteristics to produce more objective diagnoses and facilitate early identification [7,8]. AI also supports individualized treatment by predicting therapy responses, advancing precision psychiatry [10], and AI-enhanced chatbots and mobile health apps have lowered depressive symptoms while increasing access to care [11]. Nonetheless, data privacy, algorithmic bias, interpretability, and ethical issues remain major barriers to adoption [2], and emerging evidence suggests inappropriate use of AI may adversely affect mental health, underscoring the need for careful regulation [12]. This review examines how AI's role in depression care is evolving from early detection to personalized treatment, alongside existing barriers and future opportunities.

2. Artificial Intelligence Techniques in Depression Research

2.1. Machine Learning and Deep Learning

ML and DL are revolutionizing the understanding of MDD by identifying hidden patterns in high-dimensional clinical and behavioral data [13]. ML algorithms such as Support Vector Machines (SVM), Random Forest (RF), Logistic Regression, and Gradient Boosting are commonly used for diagnosis and prediction, leveraging structured data including electronic health records (EHRs), symptom surveys, and physiological measures [14]. DL automatically extracts features from unstructured data such as text, speech, images, and brain imaging [15], and unlike traditional ML captures feature relationships and temporal associations, modeling symptom evolution over time; reviews report DL outperforms ML for depression detection, especially with multimodal data [16]. CNNs process facial emotion and neuroimaging data, while RNNs and long short-term memory (LSTM) networks analyze temporal speech and behavioral data [17]. Explainable AI (XAI) techniques such as SHAP and attention mechanisms reveal which features drive predictions, building clinician trust [18]. ML and DL also predict treatment response and track progression, with hybrid models validated for antidepressant efficacy [19] and relapse risk. Obstacles include overfitting, limited generalizability, inadequate labeled data, and algorithmic bias affecting accuracy and fairness [20].

2.2. Natural Language Processing

NLP has become essential for analyzing written and spoken language to assess emotional states over time, drawing on sources such as social media content, clinical notes, chat transcripts, and patient interviews [21]. Sentiment analysis gauges emotional tone and polarity; more advanced models use semantic analysis, topic modeling, and contextual embeddings via transformer architectures such as BERT and GPT [22]. These models consider word choice, syntax, and structure to link language with depression and classify subtypes [23]. Large language models (LLMs) further improve analysis of long-form and conversational text, detecting subtle markers such as reduced lexical diversity, increased first-person pronoun use, and negative affect [24]. NLP also powers conversational agents and chatbots that engage users to collect mental health data and deliver personalized support, successfully reducing depressive symptoms [25]. Speech-based detection is a developing field, exploiting connections between speech rate, pause duration, vocal tone, and depression severity [26]. Challenges include data privacy, linguistic diversity, and annotated-data quality; social media data may not represent clinical populations, and training bias affects fairness and generalizability [27]. Still, NLP offers a non-invasive, scalable means of assessing mental health.

2.3. Multimodal Data Analysis

Multimodal data analysis (MDA) integrates multiple sources – text, speech, facial expression, physiological signals, and neuroimaging – to improve diagnostic and predictive accuracy [28]. By examining both observable behavior and biological processes, MDA provides a more holistic view than unidimensional approaches; combining EEG, facial expression, and speech analysis yields higher classification accuracy than any single source [29]. Deep architectures including multimodal transformers, fusion networks, and attention-based models learn complex cross-modal relationships and improve feature fusion [30]. Multimodal systems show improved accuracy and AUC versus unimodal systems, with one systematic

review reporting an AUC of 0.95 for depression screening [31]. They also enable continuous passive monitoring via wearables and phones, with digital phenotyping of activity, sleep, and social interaction generating valuable insights [32]. Challenges include data alignment, data loss, computational demands, and privacy and security concerns; standardized datasets and reliable fusion strategies remain essential [33].

3. AI for Early Detection of Depression

3.1. Digital Phenotyping

Digital phenotyping collects behavioral and physiological data from smartphones, wearables, and digital platforms to support early detection, enabling monitoring without traditional psychiatric evaluations [34] and capturing real-world patterns outside clinical settings [35]. Smartphones continually collect movement, sleep, communication, screen-usage, typing, and social-interaction data; reduced mobility, irregular sleep, lower communication, and increased screen time are associated with depressive symptoms [36]. ML models (SVM, RF, gradient boosting, deep neural networks) process this high-dimensional data to identify patterns not easily observed in routine assessment [37]. Combining ecological momentary assessment (EMA) of self-reported states with passive sensing provides both subjective and objective indicators, improving accuracy in tracking symptom fluctuations versus self-report alone [38,39]. Wearables add physical activity, heart rate variability, sleep efficiency, and circadian patterns [40], and multimodal systems integrating these signals outperform unimodal ones [41]. Limitations include variability in usage and devices, small samples, inconsistent methodologies, and privacy and ethical concerns from continuous sensitive-data collection [42].

3.2. Speech, Facial Expression, and Behavioral Analysis

Speech, facial expressions, and behavioral activity are strongly associated with depression, enabling objective, continuous AI-based detection that reduces reliance on self-report [42]. Depressed individuals show slower speech, lower vocal intensity, monotonic tone, reduced pitch variability, and longer pauses [44]; AI extracts acoustic and linguistic features for ML classification, with CNN and RNN models showing promising performance [45]. NLP evaluates emotional and linguistic content, observing more negative, self-focused, and hopeless language, with LLMs improving contextual interpretation [46]. Computer-vision facial analysis examines reduced expressiveness, decreased eye contact, gaze, blink rate, and facial action units, with CNNs detecting subtle changes missed in routine assessment [47]. Behavioral assessment evaluates movement, gesture frequency, typing, posture, and activity, capturing psychomotor slowing and reduced social interaction via smartphone sensors, wearables, and video [48]. Multimodal systems outperform unimodal approaches because depression alters emotional expression across modalities simultaneously [49]. Generalizability is limited by cultural, linguistic, and social variation, dataset underrepresentation, and environmental factors such as lighting, recording quality, and noise [50].

3.3. Social Media and Wearable Data

Social media platforms and wearable devices increasingly support AI-based early detection by continuously monitoring language, online activity, emotional expression, sleep, heart rate, and physical activity [51]. Platforms such as Twitter, Reddit, Facebook, and Instagram contain content reflecting emotional states; ML, NLP, and sentiment analysis identify negative expression, hopelessness, and social withdrawal, potentially before formal diagnosis [52]. LLMs improve understanding of semantic meaning, context, and emotional tone, and XAI improves transparency in social-media-based prediction [53]. Beyond text, AI analyzes behavioral and visual data – depressed users tend to post darker images and show reduced engagement – and multimodal frameworks outperform text-only systems [41]. Wearables measure heart rate, sleep quality, step count, stress, and activity; because depression is associated with sleep disturbance, reduced activity, and altered circadian rhythms, these features support detection [54], and combining wearable, smartphone, and social media data improves accuracy [55]. Concerns remain regarding privacy, informed consent, data security, training bias, and device-dependent reliability [56].

4. AI in Clinical Diagnosis and Prediction

4.1. Predictive Modeling and Risk Assessment

Predictive modeling uses ML to identify individuals at risk for depression from longitudinal and cross-sectional data, often before clinical diagnosis [57]. EHRs are widely used, with EHR-derived models reporting AUC values of 0.70–0.90 [57]; a multi-institutional study used XGBoost and logistic regression to predict progression from mild to moderate or severe depression, achieving AUCs of 0.78–0.80 and identifying diagnostic codes and symptom trajectories as key predictors [58]. Tools increasingly incorporate self-reported, lifestyle, and socioeconomic factors; a 2025 XAI study reported gradient-boosted trees and lasso regression identifying high-risk individuals with about 90% accuracy, with sleep disturbance, social isolation, and perceived stress as important features [59]. Hybrid approaches combining symptom scales, smartphone usage, and biomarkers outperform single-dimensional assessment [60]. In geriatric populations, adding comorbidities, functional impairment, and social support improves performance [61], and interpretable approaches such as SHAP enhance clinician trust [62]. Many models use convenience samples with limited diversity; multicenter prospective validation, harmonized outcome definitions, and transparent reporting of calibration and fairness are needed before widespread implementation [7].

4.2. Neuroimaging and Biomarkers

Neuroimaging-based AI offers objective, biologically informed classification of depression. Classifiers based on structural and functional MRI (sMRI, fMRI) can differentiate MDD from healthy individuals with accuracy comparable to expert diagnosis, especially with ensemble and deep learning [63], and models integrating cortical thickness, subcortical volume, and resting-state connectivity exceed 80% accuracy in well-characterized populations [64]. Deep-learning feature extraction identifies complex structural and functional brain features [65], while XAI identifies reproducible signatures: one study reported reduced gray matter volume in anterior cingulate cortex and insula plus altered default mode network connectivity as MDD indicators [66]. Translational research emphasizes biologically relevant, reproducible biomarkers [67]. Largescale EEG studies identify electrophysiological biomarkers whose time-frequency and source-localization features distinguish diagnostic groups and predict treatment response [68,69], and resting-state connectivity analyses reveal distinct neurophysiological subtypes [70]. Implementation remains limited by small, single-site, heterogeneous studies that hinder generalization across scanners, settings, and populations.

4.3. Clinical Decision Support Systems

AI-based clinical decision support systems (AI-CDSS) assist with risk assessment, treatment selection, and longitudinal monitoring, supporting treatment-algorithm selection, suicide-risk identification, and symptom tracking [71]. They may improve guideline-concordant care, reduce symptom severity, and shorten time to treatment, though large randomized validation remains limited. Aifred Health, for example, uses ML trained on historical treatment-response data with explainable decision-making to support antidepressant selection and dosage [72]. EHR-based ML can predict antidepressant response from baseline severity, prior diagnoses, and previous antidepressant use, supporting more personalized decisions [73]. However, many tools have not met regulatory and scientific requirements, raising concerns about transparency, reproducibility, external validation, and standards such as CONSORT-AI [74]; successful integration requires workflow integration, real-time feedback, and continuous performance monitoring to minimize alert fatigue and bias [75]. Small, homogeneous datasets limit generalizability, and over-reliance without oversight may weaken shared decision-making [74,75]. Future work should integrate AI-CDSS with digital phenotyping, embed explainable outputs into workflows, and develop equity-focused validation metrics.

5. AI-Driven Personalized Treatment

5.1. Precision Psychiatry

Precision psychiatry shifts treatment from symptom-based, trial-and-error care toward individualized, data-

driven strategies. STAR*D showed remission probability declines after multiple unsuccessful antidepressant trials, underscoring the need for personalization [76]. AI and ML integrate multimodal data – neuroimaging, genetics, EHRs, behavioral phenotyping, wearables, and symptom profiles – to identify clinically relevant subtypes not recognized by conventional frameworks [77]. ML predicts antidepressant response, symptom trajectories, and treatment resistance using demographics, inflammatory biomarkers, neurocognitive assessments, and neuroimaging, with DL capturing nonlinear relationships [78]. Neuroimaging-guided approaches pair fMRI, EEG, and structural imaging with AI to classify subtypes and predict response to medication, psychotherapy, transcranial magnetic stimulation (TMS), and electroconvulsive therapy (ECT), linking default mode, salience, and frontolimbic disturbances to differential responsiveness [79]. Genomic and transcriptomic data, polygenic risk scores, and inflammatory biomarkers such as C-reactive protein are increasingly incorporated, given immune dysregulation's link to treatment resistance [80]. Digital phenotyping enables real-time personalization through continuous monitoring [81]. Challenges include small or homogeneous datasets, bias, limited interpretability, insufficient prospective validation, and ethical concerns around privacy, consent, and transparency [82].

5.2. AI-Based Therapeutic Interventions (Including Chatbot-Assisted CBT)

AI-based therapy is increasingly used in depression treatment for improved access, scalability, and continuity of care. Chatbot therapy based on cognitive behavioral therapy (CBT) principles uses NLP, ML, and LLMs to approximate the consultant-client relationship while delivering psychoeducation, symptom monitoring, and coping strategies [83]. Chatbots such as Woebot and Wysa have shown improvements in depressive and anxiety symptoms versus traditional or no treatment, using structured conversations, mood tracking, journaling, and personalized recommendations [84]. AI integrated into internet-delivered CBT (iCBT) analyzes longitudinal symptom progression and interaction data to predict outcomes and identify patients at risk of poor engagement or dropout, enabling early intervention [85]. AI-assisted interventions also support telepsychiatry, combining automated screening, mood monitoring, and chatbot-guided support with clinician supervision [86]. Evidence remains limited by small samples, short follow-up, and heterogeneous methods, and long-term and comparative efficacy versus face-to-face therapy is insufficiently established [84]. Ethical and clinical concerns include inaccurate or insensitive responses – particularly around suicidality or emergencies – and issues of privacy, emotional dependency, transparency, and accountability [87].

5.3. Treatment Monitoring and Relapse Prediction

Given depression's recurrent, episodic nature, ongoing monitoring and early relapse identification are critical. Traditional periodic assessments and self-reports may miss subtle pre-relapse changes, motivating AI-based monitoring for real-time, longitudinal, personalized assessment [88]. ML analyzing EHRs, questionnaires, wearables, smartphone sensors, speech, sleep, activity, and social interaction enables earlier recognition of relapse-associated changes than clinic-based follow-up [89]. Digital phenotyping detects deviations from individual baselines before relapse [90], and one longitudinal study combining self-report with wearable activity monitoring predicted relapse several weeks before onset within a "predict-and-prevent" framework [91]. NLP monitors cognitive and emotional changes through speech tempo, acoustics, sentiment, and linguistic complexity [92], while AI-assisted CBT monitoring identifies patients needing treatment modification, including in iCBT [93]. Remote monitoring benefits telepsychiatry and community settings, reducing reliance on in-person visits and improving adherence and engagement [94]. Challenges include small samples limiting generalizability and performance variation across demographic, cultural, and socioeconomic groups [95].

5.4. mHealth, Telepsychiatry, and AI-Based Mental Health Tools

mHealth, telepsychiatry, and AI have transformed depression treatment, improving access in underserved regions through remote monitoring and continuity of care, supported by advances in ML, NLP, and wearables [96]. AI-integrated mobile apps help patients monitor mood, sleep, cognition, adherence, and activity in real time while delivering psychoeducation, behavioral activation, mindfulness, and CBT tailored to individual needs [97]. Mental health chatbots and conversational AI use NLP and DL to simulate

therapist-client dialogue, assess distress, and provide support; evaluations of platforms such as Wysa show benefits for emotional support, accessibility, and engagement, and some detect suicidal ideation and recommend referral [98]. Telepsychiatry grew rapidly after COVID-19, with AI supporting triage, symptom tracking, risk stratification, and documentation, and analyzing speech, facial expressions, and behavior during virtual consultations; reviews suggest improved diagnostic efficiency and continuous monitoring [99]. AI can also augment therapy by summarizing sessions, monitoring progress, and identifying dropout risk, reducing administrative burden and supporting measurement-based care [100].

6. Challenges and Ethical Considerations

6.1. Data Privacy, Bias, and Ethical Concerns

AI in depression care raises challenges of data privacy, algorithmic bias, transparency, accountability, and ethical regulation, given the sensitivity of mental health data. AI relies on data from EHRs, wearables, mobile apps, voice, and social media, raising privacy and consent concerns; inadequate protection can cause stigma, discrimination, and surveillance, eroding confidence [101,102]. Protecting data from breaches is critical, as systems require regular access to private behavioral and emotional data [103], yet many applications lack explicit data-protection guidelines [104], and passive sensing of phone use, geolocation, and sleep threatens consent when users are unaware of processing [105]. Federated learning and privacy-preserving ML are proposed safeguards [106]. Algorithmic bias is a second challenge: models trained on narrow ethnic, linguistic, or socioeconomic groups may underperform for others [107], with systems trained on English-speaking Western populations failing in culturally diverse groups [108], and one study showing lower accuracy for Black than White Americans [109]. Such bias risks inaccurate diagnosis and widening disparities, motivating representative datasets, fairness-aware algorithms, and ongoing validation [110]. The "black box" problem limits understanding of decisions [111], complicating accountability; XAI is a potential solution [112]. Finally, psychotherapy chatbots [113] may respond inappropriately to suicidality, psychosis, or severe depression [114], and over-reliance may impair the therapeutic relationship [115]. Ethical governance emphasizing transparency, responsibility, equity, informed consent, and human-centric design is essential [116].

6.2. Clinical Validation and Regulatory Challenges

Despite progress, clinical and regulatory barriers hinder integration. Tools showing high precision in research often have questionable real-world utility [117], as many were trained on retrospective, small, or single-site datasets that limit generalizability [118], with internal validity decreasing substantially in external validation. The absence of validated guidelines and varied datasets, diagnostic approaches, and metrics make model comparison impractical [119], and curated training data may not reflect realities of comorbidity, diversity, and incomplete records. Randomized controlled trials are needed to assess clinical utility [19], and overfitting causes performance drops in external validation [120], amplified by depression's variation across age, ethnicity, and culture. "Black box" deep learning generates predictions without transparent reasoning [121], reducing adoption given psychiatry's reliance on subjective evaluation; XAI offers clarity but is rarely implemented [122]. Regulation poses further challenges, as medical-device frameworks were not designed for AI that updates after deployment, and the FDA and EMA still struggle to ensure safety, reliability, and accountability [123]. Most mental health AI lacks rigorous approval or post-marketing monitoring, with legal liability, accountability, software updates, and risk management hindering certification [124], and the lack of objective biological measures complicates frameworks because behavioral, speech, phone-activity, and social-media indicators vary by environment and time [125]. Ethical responsibility raises questions of who is liable for erroneous diagnosis or recommendations – practitioner, facility, or developer [126] – prompting calls for governance including independent audits, monitoring, standardized reporting, and human supervision [119].

7. Future Directions

Future research should move beyond proof-of-concept prediction toward clinically reliable, explainable, and equitable systems integrated into routine workflows. Although multimodal AI may improve identification

and risk stratification, dataset heterogeneity, inconsistent outcome definitions, and limited external validation restrict translation. A priority is models trained on diverse populations and validated across multiple settings, since performance may not generalize across language, culture, access, and symptom presentation [127]. Integrating multimodal longitudinal data – speech, text, passive smartphone sensing, wearables, digital phenotyping, and biomarkers – is important because single-time-point classifiers cannot capture fluctuations in severity, relapse risk, or treatment response, requiring robust missing-data handling, transparent feature selection, and interpretable outputs [128]. Personalized treatment is expected to advance, with AI helping select medications, psychotherapy, neuromodulation, or combined strategies based on predicted response, though prospective validation is required [129]. The most valuable applications are likely decision-support systems that enhance rather than replace clinician judgment, particularly for suicidality, comorbidity, and treatment-resistant depression, evaluated not only for accuracy but for improving remission, reducing delays, and enhancing engagement [130]. Safe implementation requires transparency, interpretability, and governance – interpretable architectures, calibration, uncertainty estimation, bias assessment, and transparent documentation – while addressing privacy, consent, data security, and disparities [30]. Progress will depend on pragmatic trials and implementation science comparing AI against standard care on accessibility, acceptability, efficiency, safety, and cost-effectiveness, sustained by interdisciplinary collaboration among psychiatrists, data scientists, ethicists, and health leaders [131,132].

8. Conclusion

AI is rapidly transforming depression care by enabling earlier detection, more objective diagnosis, continuous monitoring, and personalized treatment. This review highlights how machine learning, deep learning, NLP, multimodal analysis, digital phenotyping, neuroimaging, wearables, and AI-assisted therapeutic tools are reshaping psychiatry, identifying depressive symptoms through behavioral, linguistic, physiological, and neurobiological markers while supporting predictive modeling, relapse prevention, and precision psychiatry. Emerging digital tools – chatbot-assisted CBT, telepsychiatry, and mobile health applications – may improve accessibility and continuity, particularly in underserved populations. Significant challenges remain, including dataset heterogeneity, algorithmic bias, limited external validation, poor interpretability, privacy concerns, and insufficient regulatory oversight, with many systems relying on retrospective or demographically restricted datasets that reduce fairness and generalizability. Ethical concerns of consent, data governance, accountability, and over-reliance must be addressed for safe implementation. Future progress depends on clinically validated, explainable, patient-centered systems that complement clinician expertise, supported by large prospective studies, standardized reporting, multimodal longitudinal datasets, and interdisciplinary collaboration. AI should be viewed not merely as a technological innovation but as a supportive clinical tool capable of improving diagnostic precision, optimizing outcomes, reducing disparities, and enhancing mental healthcare quality. With appropriate governance and validation, AI may become an integral component of future depression care and digital psychiatry.

Declarations

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest: The authors declare no conflict of interest.

Ethical Approval: Not applicable.

Data Availability: Not applicable.

References

[1] Aleagha DM, et al. AI Models for Depressive Disorder Detection and Diagnosis: A Review. arXiv preprint arXiv:2508.12022 (2025).

[2] Ali M, et al. Artificial intelligence for mental health: A narrative review of applications, challenges, and future directions in digital health. Digital Health 2025.

[3] Joshi AC, et al. Systematic review of artificial intelligence enabled psychological interventions for depression and anxiety: A comprehensive analysis. Industrial Psychiatry Journal 2025.

[4] Liţan DE. Mental health in the “era” of artificial intelligence: technostress and the perceived impact on anxiety and depressive disorders—an SEM analysis. Frontiers in Psychology 2025.

[5] Nassibi A, et al. A Systematic Review of EEG-based Machine Intelligence Algorithms for Depression Diagnosis, and Monitoring. arXiv preprint arXiv:2503.19820 (2025).

[6] Benrimoh D, et al. Development of the treatment prediction model in the artificial intelligence in depression–medication enhancement study. NPJ Mental Health Research 2025.

[7] Park Y, et al. Effectiveness of artificial intelligence in detecting and managing depressive disorders: Systematic review. Journal of Affective Disorders 2024.

[8] Ali M, et al. Artificial intelligence for mental health: A narrative review of applications, challenges, and future directions in digital health. Digital Health 2025.

[9] Wajid A, et al. Applications of artificial intelligence in mental health: a systematic literature review. Discover Artificial Intelligence 2025.

[10] Feng Y, et al. Effectiveness of AI-driven conversational agents in improving mental health among young people: systematic review and meta-analysis. Journal of medical Internet research 2025.

[11] Hull TD, et al. Generative AI Purpose-built for Social and Mental Health: A Real-World Pilot. arXiv preprint arXiv:2511.11689 (2025).

[12] Perlis RH, et al. Generative AI use and depressive symptoms among US adults. JAMA Network Open 2026.

[13] Ahmed I, et al. Explainable ai for depression detection and severity classification from activity data: Development and evaluation study of an interpretable framework. JMIR Mental Health 2025.

[14] Xia F, et al. A machine learning-based depression risk prediction model for healthy middle-aged and older adult people based on data from the China health and aging tracking study. Frontiers in Public Health 2025.

[15] Song S, et al. Automatic Depression Assessment using Machine Learning: A Comprehensive Survey. arXiv preprint arXiv:2506.18915 (2025).

[16] Pandya A, et al. Evaluating Current Trends in Stress and Depression Detection Using Artificial Intelligence and Machine Learning. Intelligent Hospital 2026.

[17] Alakananda K, et al. An AI-Driven Hybrid Approach for Detecting Mental Health Indicators in Multilingual Indian Social Media: Data Acquisition and Analytical Frameworks. Engineering, Technology & Applied Science Research 2026.

[18] Mimikou C, et al. Explainable machine learning in the prediction of depression. Diagnostics 2025.

[19] Yadav N, et al. Evaluating the impact of machine learning models on adult major depressive disorder using conventional treatment strategies: a systematic review approach. Discover Public Health 2025.

[20] Alakananda K, et al. An AI-Driven Hybrid Approach for Detecting Mental Health Indicators in Multilingual Indian Social Media: Data Acquisition and Analytical Frameworks. Engineering, Technology & Applied Science Research 2026.

[21] Fisher H, et al. Language-based detection of depression with machine learning: systematic review and meta-analysis. npj Digital Medicine 2026.

[22] Devlin J, et al. Bert: Pre-training of deep bidirectional transformers for language understanding. In Proceedings of the 2019.

[23] Brown T, et al. Language models are few-shot learners. Advances in neural information processing systems 2020.

[24] Wan Q, et al. Analyzing depression in college students using nlp and transformer models: Implications for career and educational counseling. Brain and Behavior 2025.

[25] Sohn JS, et al. Systematic review and meta analysis of chatbots in the management of depressive and anxiety symptoms. npj Digital Medicine 2026.

[26] Elie B, et al. A glottal chink model for the synthesis of voiced fricatives. In 2016 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP) 2016.

[27] Wang L, et al. AI-assisted multi-modal information for the screening of depression: a systematic review and meta-analysis. NPJ Digital Medicine 2025.

[28] Li Q, et al. Machine learning-based prediction of depressive disorders via various data modalities: a survey. IEEE/CAA Journal of Automatica Sinica 2025.

[29]Hong JS, et al. Exploring Machine Learning and Language Models for Multimodal Depression Detection. In 2025 Asia Pacific Signal and Information Processing Association Annual Summit and Conference (APSIPA ASC) 2025.

[30]Ghorbankhani M, et al. Artificial intelligence in depression diagnostics: A systematic review of methodologies and clinical applications. Artificial Intelligence in Medicine 2025.

[31]Yao B, et al. More Modality, More AI: Exploring Design Opportunities of AI-Based Multi-modal Remote Monitoring Technologies for Early Detection of Mental Health Sequelae in Youth Concussion Patients. arXiv preprint arXiv:2502.03732 (2025).

[32]Kambar T, et al. AI in Mental Health: Transforming Diagnosis and Management of Depression and Anxiety. Health Science Reports 2026.

[33]Fatima E, et al. AI-Driven Detection of Stress, Anxiety, and Depression: Techniques, Challenges, and Future Perspectives. In 2025 3rd International Conference on Disruptive Technologies (ICDT) 2025.

[34]Chen K, et al. The Current State/Trends in Digital Phenotyping for Mental Health Research and Care. Psychiatric Clinics 2025.

[35]Heckler WF, et al. Digital phenotyping for mental health based on data analytics: A systematic literature review. Artificial intelligence in medicine 2025.

[36]Leaning IE, et al. From smartphone data to clinically relevant predictions: A systematic review of digital phenotyping methods in depression. Neuroscience & Biobehavioral Reviews 2024.

[37]Hoang H, et al. Advancing mental health diagnostics: a review on the role of smartphones, wearable devices, and artificial intelligence in depression and anxiety detection. Biomedical Engineering Letters 2025.

[38]Tutunji R, et al. Integrating ecological momentary and passive sensing data to improve depression severity prediction: Insights from the WARN-D study.

[39]Czyz EK, et al. Ecological momentary assessments and passive sensing in the prediction of short-term suicidal ideation in young adults. JAMA Network Open 2023.

[40]Borghare PT, et al. A comprehensive review on harnessing wearable technology for enhanced depression treatment. Cureus 2024.

[41]Sadeghi M, et al. Harnessing multimodal approaches for depression detection using large language models and facial expressions. npj Mental Health Research 2024.

[42]Adam D. Digital phenotyping using smartphones could help steer mental health treatment.Proceedings of the National Academy of Sciences 2025.

[43]Joshi ML, et al. Depression detection using emotional artificial intelligence and machine learning: A closer review. Materials Today: Proceedings 2022.

[44]Liu L, et al. Diagnostic accuracy of deep learning using speech samples in depression: a systematic review and meta-analysis. Journal of the American Medical Informatics Association 2024.

[45]Donaghy P, et al. A review of studies using machine learning to detect voice biomarkers for depression. Journal of Technology in Behavioral Science 2024.

[46]Wang Y, et al. Explainable depression detection using large language models on social media data. In Proceedings of the 9th Workshop on Computational Linguistics and Clinical Psychology (CLPsych) 2024.

[47]Zhao Q. Process analysis of facial expressions, movements, and psychological changes in depression based on deep learning algorithms. J Biotech Res 2025.

[48]Sobin C. Psychomotor symptoms of depression. American Journal of Psychiatry 1997.

[49]Khoo LS, et al. Machine learning for multimodal mental health detection: a systematic review of passive sensing approaches. Sensors 2024.

[50]Cao Y, et al. Machine learning approaches for mental illness detection on social media: A systematic review of biases and methodological challenges. arXiv preprint arXiv:2410.16204 (2024).

[51]Islam MM, et al. A comprehensive review of predictive analytics models for mental illness using machine learning algorithms. Healthcare Analytics 2024.

[52]Lan X, et al. Depression detection on social media with large language models. In Proceedings of the 2025.

[53]Ge Z, et al. A survey of large language models in mental health disorder detection on social media. In 2025 IEEE 41st International Conference on Data Engineering Workshops (ICDEW) 2025.

[54]Liu JJ, et al. Digital phenotyping from wearables using AI characterizes psychiatric disorders and

identifies genetic associations. Cell 2025.
[55]Vander Zwalmen Y, et al. Mobile technology for just-in-time prediction of depression: a scoping review. Nature Mental Health 2026.
[56]Yeasmin S, et al. Artificial Intelligence for Mental Health Monitoring: A Solution for Digital Behavioral Health Care and Education—An Umbrella Review. Health Science Reports 2026.
[57]Nickson D, et al. Prediction and diagnosis of depression using machine learning with electronic health records data: a systematic review. BMC medical informatics and decision making 2023.
[58]Ahadian P, et al. Development and Validation of Machine Learning-Based Prediction of Depression Progression Using EHR Data: A Multi-Institutional Retrospective Cohort Study. medRxiv 2025.
[59]ShamsEldin T, et al. Artificial intelligence for predicting depression anxiety and stress using psychometric data. Scientific Reports 2025.
[60]Benito GV, et al. Machine learning for anxiety and depression profiling and risk assessment in the aftermath of an emergency. Artificial Intelligence in Medicine 2024.
[61]Yang J, et al. Machine Learning-Based Depression Risk Prediction Models for Older Adults Analyzing From the Perspective of the Health Ecology Model: A Scoping Review. Neuropsychiatric Disease and Treatment 2026.
[62]Lewin G, et al. Artificial intelligence-enabled predictive modelling in psychiatry: overview of machine learning applications in mental health research. BJPsych Advances 2025.
[63]Zheng YJ, et al. Evaluating the potential of applying artificial intelligence in the diagnosis of major depressive disorder: Neuroimaging and clinical behavioral markers. Journal of Affective Disorders 2026.
[64]Gallucci J, et al. A systematic review of structural and functional magnetic resonance imaging studies on the neurobiology of depressive symptoms in schizophrenia spectrum disorders. Schizophrenia 2024.
[65]Vieira S, et al. Using deep learning to investigate the neuroimaging correlates of psychiatric and neurological disorders: Methods and applications. Neuroscience & Biobehavioral Reviews 2017.
[66]Mao L, et al. Identifying neuroimaging biomarkers in major depressive disorder using machine learning algorithms and functional near-infrared spectroscopy (fNIRS) during verbal fluency task. Journal of affective disorders 2024.
[67]Woo CW, et al. Building better biomarkers: brain models in translational neuroimaging. Nature neuroscience 2017.
[68]Zhai L, et al. A systematic review of EEG-based biomarkers for depression, anxiety, and bipolar disorder: trends in explainable artificial intelligence (XAI). BMC psychiatry 2025.
[69]Fonseka TM, et al. Neuroimaging biomarkers as predictors of treatment outcome in major depressive disorder. Journal of affective disorders 2018.
[70]Drysdale AT, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nature medicine 2017.
[71]Chiang MA, et al. A Systematic Review on Artificial Intelligence-Based Clinical Decision Support Systems in Depression. In 2025 47th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) 2025.
[72]Golden G, et al. Applying artificial intelligence to clinical decision support in mental health: What have we learned? Health Policy and Technology 2024.
[73]Chekroud AM, et al. Cross-trial prediction of treatment outcome in depression: a machine learning approach. The Lancet Psychiatry 2016.
[74]Kleine AK, et al. AI-enabled clinical decision support tools for mental healthcare: A product review. Artificial Intelligence in Medicine 2025.
[75]Ali M, et al. Artificial intelligence for mental health: A narrative review of applications, challenges, and future directions in digital health. Digital Health 2025.
[76]Laifenfeld D, et al. Toward precision psychiatry: Innovations and prospects in treating depression. The primary care companion for CNS disorders 2025.
[77]Chen ZS, et al. Modern views of machine learning for precision psychiatry. Patterns 2022.
[78]Pettorruso M, et al. Overcoming treatment-resistant depression with machine-learning based tools: a study protocol combining EEG and clinical data to personalize glutamatergic and brain stimulation interventions (SelecTool Project). Frontiers in psychiatry 2024.

[79]Jalali S, et al. The Use of Artificial Intelligence for Personalized Treatment in Psychiatry. Current Psychiatry Reports 2025.

[80]Adeyemi-Benson OS. Precision Psychiatry: Leveraging Multi-omics and AI for Personalized Mental Health Treatment. Med-informatics 2025.

[81]Vairavan S, et al. Personalized relapse prediction in patients with major depressive disorder using digital biomarkers. Scientific reports 2023.

[82]Cruz-Gonzalez P, et al. Artificial intelligence in mental health care: a systematic review of diagnosis, monitoring, and intervention applications. Psychological medicine 2025.

[83]Im CH, et al. Clinical Efficacy, Therapeutic Mechanisms, and Implementation Features of Cognitive Behavioral Therapy– Based Chatbots for Depression and Anxiety: Narrative Review. JMIR Mental Health 2025.

[84]Zhong W, et al. The therapeutic effectiveness of artificial intelligence-based chatbots in alleviation of depressive and anxiety symptoms in short-course treatments: a systematic review and meta-analysis. Journal of affective disorders 2024.

[85]Prasad N, et al. Deep learning for the prediction of clinical outcomes in internet-delivered CBT for depression and anxiety. Plos one 2023.

[86]Bobkov A, et al. Telepsychiatry and artificial intelligence: a structured review of emerging approaches to accessible psychiatric care. In Healthcare 2025.

[87]Meadi MR, et al. Exploring the ethical challenges of conversational AI in mental health care: scoping review. JMIR mental health 2025.

[88]Yasin S, et al. Machine learning based approaches for clinical and non-clinical depression recognition and depression relapse prediction using audiovisual and EEG modalities: A comprehensive review. Computers in Biology and Medicine 2023.

[89]Othmani A, et al. A multimodal computer-aided diagnostic system for depression relapse prediction using audiovisual cues: A proof of concept. Healthcare Analytics 2022.

[90]Ni Y, et al. A scoping review of AI-driven digital interventions in mental health care: mapping applications across screening, support, monitoring, prevention, and clinical education. In Healthcare 2025.

[91]Amin R, et al. Use of Mobile Sensing Data for Longitudinal Monitoring and Prediction of Depression Severity: Systematic Review. Journal of Medical Internet Research 2025.

[92]Zhang X, et al. When llms meets acoustic landmarks: An efficient approach to integrate speech into large language models for depression detection. In Proceedings of the 2024.

[93]Roemmel N, et al. Prediction of treatment outcome in patients receiving internet-delivered cognitive behavioural therapy for depressive and anxiety symptoms: a machine learning analysis of data from a healthcare-embedded longitudinal study. BMJ open 2025.

[94]Perez K, et al. Investigation into application of AI and telemedicine in rural communities: a systematic literature review. In Healthcare 2025.

[95]Chen ZS, et al. A cautionary tale for AI and machine learning in psychiatry. Translational Psychiatry 2026.

[96]Hebbar S, et al. Artificial intelligence in future telepsychiatry and psychotherapy for e-mental health revolution. In Computational Intelligence in Medical Decision Making and Diagnosis 2023.

[97]Gkintoni E, et al. Next-generation cognitive-behavioral therapy for depression: integrating digital tools, teletherapy, and personalization for enhanced mental health outcomes. Medicina 2025.

[98]Hua Y, et al. Charting the evolution of artificial intelligence mental health chatbots from rule-based systems to large language models: a systematic review. World Psychiatry 2025.

[99]Di Carlo F, et al. Telepsychiatry and other cutting-edge technologies in COVID-19 pandemic: Bridging the distance in mental health assistance. International journal of clinical practice 2021.

[100] Gutierrez G, et al. Examining the role of AI technology in online mental healthcare: opportunities, challenges, and implications, a mixed-methods review. Frontiers in psychiatry 2024.

[101] Squires M, et al. Deep learning and machine learning in psychiatry: a survey of current progress in depression detection, diagnosis and treatment. Brain Informatics 2023.

[102] Rogan J, et al. Health care professionals' views on the use of passive sensing, AI, and machine learning in mental health care: systematic review with meta-synthesis. JMIR Mental Health 2024.

[103] Beg MJ, et al. Artificial intelligence for psychotherapy: a review of the current state and future directions. Indian journal of psychological medicine 2025.

[104] Malgaroli M, et al. Natural language processing for mental health interventions: a systematic review and research framework. Translational Psychiatry 2023.

[105] Tornero-Costa R, et al. Methodological and quality flaws in the use of artificial intelligence in mental health research: systematic review. JMIR Mental Health 2023.

[106] Coghlan S, et al. To chat or bot to chat: Ethical issues with using chatbots in mental health. Digital health 2023.

[107] Guo Z, et al. Large language models for mental health applications: systematic review. JMIR mental health 2024.

[108] Pandey HM. Artificial intelligence in mental health and well-being: Evolution, current applications, future challenges, and emerging evidence. arXiv preprint arXiv:2501.10374 (2024).

[109] Green MC, et al. Social Media, Artificial Intelligence, and Digital Well-Being: Research Contributions and Policy Challenges. Social and Personality Psychology Compass 2025.

[110] Ni Y, et al. A scoping review of AI-driven digital interventions in mental health care: mapping applications across screening, support, monitoring, prevention, and clinical education. In Healthcare 2025.

[111] Koutelov R. Human and Artificial Intelligence: Fear, Functional Subjecthood, and the Charter of Symbiosis. Available at SSRN 2026.

[112] PR B, et al. Algorithmic solutions, subjectivity and decision errors: a study of AI accountability. Digital Policy, Regulation and Governance 2025.

[113] Shumate JN, et al. Governing AI in mental health: 50-state legislative review. JMIR Mental Health 2025.

[114] Jafar A, et al. Artificial Intelligence in Mental Healthcare: Opportunities, Risks, and Regulations. In AI in Mental Health: Innovations, Challenges, and Collaborative Pathways 2025.

[115] Smith A, et al. “It’s a complicated issue”: exploring perspectives on Reddit from 2016 to 2024 about the American Psychiatric Association’s Goldwater Rule and the ethics of public-professional mental health commentary. BMC Medical Ethics 2026.

[116] Ren W, et al. AI Applications in Depression Detection and Diagnosis: Bibliometric and Visual Analysis of Trends and Future Directions. JMIR Mental Health 2025.

[117] Okesanya OJ, et al. Applications of artificial intelligence and machine learning in the diagnosis and management of major depressive disorder: a systematic review. The Egyptian Journal of Neurology, Psychiatry and Neurosurgery 2026.

[118] Mao K, et al. A systematic review on automated clinical depression diagnosis. Npj mental health research 2023.

[119] Abu-Mahfouz MS, et al. Artificial intelligence in mental health care: a scoping review of reviews. Frontiers in Psychiatry 2026.

[120] Benrimoh D, et al. Development and validation of a deep-learning model for differential treatment benefit prediction for adults with major depressive disorder deployed in the artificial intelligence in depression medication enhancement (AIDME) study. arXiv preprint arXiv:2406.04993 (2024).

[121] Stroud AM, et al. Physician perspectives on the potential benefits and risks of applying artificial intelligence in psychiatric medicine: qualitative study. JMIR mental health 2025.

[122] Sathyapriya B, et al. Artificial intelligence and Mental Health Care Practices.

[123] Field H, et al. Google’s healthcare AI made up a body part – what happens when doctors don’t notice? The Verge 2025.

[124] Pigg E. Societal digitalization and AI avatars in healthcare context.

[125] Zhong Z, et al. Intelligent Depression Prevention via LLM-Based Dialogue Analysis: Overcoming the Limitations of Scale-Dependent Diagnosis through Precise Emotional Pattern Recognition. arXiv preprint arXiv:2504.16504 (2025).

[126] Tecco H. Massively Better Healthcare: The Innovator’s Guide to Tackling Healthcare’s Biggest Challenges. Columbia University Press 2026.

[127] Ricci F, Giallanella D, Gaggiano C, Torales J, Castaldelli-Maia JM, Liebrenz M, Bener A, Ventriglio A. Artificial intelligence in the detection and treatment of depressive disorders: a narrative review of literature. International Review of Psychiatry. 2025 Jan 2;37(1):39-51.

[128] Zafar F, et al. The role of artificial intelligence in identifying depression and anxiety: a comprehensive literature review. Cureus 2024.

[129] Arnold PI, et al. Machine learning for antidepressant treatment selection in depression. Drug Discovery Today 2024.

[130] Alemi F, et al. Artificial Intelligence for Management of Major Depression: Initial Design, Progress, and Research Plans. Alpha Psychiatry 2025.

[131] Sun J, et al. Practical AI application in psychiatry: historical review and future directions. Molecular Psychiatry 2025.

[132] Kellogg KC, et al. Pragmatic AI-augmentation in mental healthcare: key technologies, potential benefits, and real-world challenges and solutions for frontline clinicians. Frontiers in psychiatry 2022.